100 related articles for article (PubMed ID: 16084547)
1. Phase I safety study of Praneem polyherbal vaginal tablet use among HIV-uninfected women in Pune, India.
Joshi SN; Katti U; Godbole S; Bharucha K; B KK; Kulkarni S; Risbud A; Mehendale S
Trans R Soc Trop Med Hyg; 2005 Oct; 99(10):769-74. PubMed ID: 16084547
[TBL] [Abstract][Full Text] [Related]
2. Acceptability of Praneem polyherbal vaginal tablet among HIV uninfected women & their male partners in Pune, India--Phase I study.
Joglekar NS; Joshi SN; Navlakha SN; Katti UR; Mehendale SM
Indian J Med Res; 2006 Apr; 123(4):547-52. PubMed ID: 16783046
[TBL] [Abstract][Full Text] [Related]
3. Expanded safety study of Praneem polyherbal vaginal tablet among HIV-uninfected women in Pune, India: a phase II clinical trial report.
Joshi SN; Dutta S; Kumar BK; Katti U; Kulkarni S; Risbud A; Mehendale S
Sex Transm Infect; 2008 Oct; 84(5):343-7. PubMed ID: 18426844
[TBL] [Abstract][Full Text] [Related]
4. A polyherbal vaginal pessary with spermicidal and antimicrobial action: evaluation of its safety.
Bagga R; Raghuvanshi P; Gopalan S; Das SK; Baweja R; Suri S; Malhotra D; Khare S; Talwar GP
Trans R Soc Trop Med Hyg; 2006 Dec; 100(12):1164-7. PubMed ID: 16750546
[TBL] [Abstract][Full Text] [Related]
5. Acceptability and adherence: findings from a Phase II study of a candidate vaginal microbicide, 'Praneem polyherbal tablet', in Pune, India.
Joglekar NS; Joshi SN; Deshpande SS; Parkhe AN; Katti UR; Mehendale SM
Trans R Soc Trop Med Hyg; 2010 Jun; 104(6):412-5. PubMed ID: 20096909
[TBL] [Abstract][Full Text] [Related]
6. Studies on the contraceptive efficacy of Praneem polyherbal cream.
Garg S; Taluja V; Upadhyay SN; Talwar GP
Contraception; 1993 Dec; 48(6):591-6. PubMed ID: 8131399
[TBL] [Abstract][Full Text] [Related]
7. Phase II clinical trial with Praneem polyherbal tablets for assessment of their efficacy in symptomatic women with abnormal vaginal discharge (an ICMR task force study).
Sharma RS; Mathur AK; Chandhiok N; Datey S; Saxena NC; Gopalan S; Sharma S; Mittal S; Sehgal R; Sumandal BK; Chanda A; Salvi V; Mutalik N; Coyaji KJ; Gibsson A; Hazari K; Kalgutkar S; Talwar GP
Trans R Soc Trop Med Hyg; 2009 Feb; 103(2):167-72. PubMed ID: 18990416
[TBL] [Abstract][Full Text] [Related]
8. Phase I safety & preliminary acceptability of nonoxynol-9 vaginal pessary as a vaginal microbicide in low risk women in Pune, India.
Joshi S; Joglekar N; Ghate M; Unni J; Risbud A; Bentley M; Shepherd M; Bollinger R; Mehendale S
Indian J Med Res; 2003 Apr; 117():152-7. PubMed ID: 14604303
[TBL] [Abstract][Full Text] [Related]
9. Spermicidal & contraceptive properties of Praneem polyherbal pessary.
Raghuvanshi P; Bagga R; Malhotra D; Gopalan S; Talwar GP
Indian J Med Res; 2001 Apr; 113():135-41. PubMed ID: 11558322
[TBL] [Abstract][Full Text] [Related]
10. A phase II randomized controlled trial to evaluate the safety and efficacy of Praneem polyherbal vaginal tablets compared with betadine vaginal pessary in women with symptoms of abnormal vaginal discharge.
Salhan S; Tripathi V; Sehgal R; Kumar G; Talwar GP; Chatterjee A
Asia Pac J Public Health; 2009 Oct; 21(4):461-8. PubMed ID: 19783561
[TBL] [Abstract][Full Text] [Related]
11. Safety of intrauterine administration of purified neem seed oil (Praneem Vilci) in women & effect of its co-administration with the heterospecies dimer birth control vaccine on antibody response to human chorionic gonadotropin.
Talwar GP; Pal R; Singh O; Garg S; Taluja V; Upadhyay SN; Gopalan S; Jain V; Kaur J; Sehgal S
Indian J Med Res; 1995 Aug; 102():66-70. PubMed ID: 8834816
[TBL] [Abstract][Full Text] [Related]
12. A randomized trial comparing a polyherbal pessary (a complementary and alternative medicine) with Ginlac-V pessary (containing clotrimazole, tinidazole and lactobacilli) for treatment of women with symptomatic vaginal discharge.
Patel Y; Gopalan S; Bagga R; Sharma M; Chopra S; Sethi S
Arch Gynecol Obstet; 2008 Oct; 278(4):341-7. PubMed ID: 18236058
[TBL] [Abstract][Full Text] [Related]
13. Safety and acceptability of cellulose sulfate as a vaginal microbicide in HIV-infected women.
El-Sadr WM; Mayer KH; Maslankowski L; Hoesley C; Justman J; Gai F; Mauck C; Absalon J; Morrow K; Mâsse B; Soto-Torres L; Kwiecien A
AIDS; 2006 May; 20(8):1109-16. PubMed ID: 16691061
[TBL] [Abstract][Full Text] [Related]
14. Safety and tolerability of tenofovir vaginal gel in abstinent and sexually active HIV-infected and uninfected women.
Mayer KH; Maslankowski LA; Gai F; El-Sadr WM; Justman J; Kwiecien A; Mâsse B; Eshleman SH; Hendrix C; Morrow K; Rooney JF; Soto-Torres L;
AIDS; 2006 Feb; 20(4):543-51. PubMed ID: 16470118
[TBL] [Abstract][Full Text] [Related]
15. Safety and tolerability of BufferGel, a novel vaginal microbicide, in women in the United States.
Mayer KH; Peipert J; Fleming T; Fullem A; Moench T; Cu-Uvin S; Bentley M; Chesney M; Rosenberg Z
Clin Infect Dis; 2001 Feb; 32(3):476-82. PubMed ID: 11170957
[TBL] [Abstract][Full Text] [Related]
16. A randomized Phase I vaginal safety study of three concentrations of C31G vs. Extra Strength Gynol II.
Mauck CK; Weiner DH; Creinin MD; Barnhart KT; Callahan MM; Bax R
Contraception; 2004 Sep; 70(3):233-40. PubMed ID: 15325893
[TBL] [Abstract][Full Text] [Related]
17. A randomized six-day safety study of an antiretroviral microbicide candidate UC781, a non-nucleoside reverse transcriptase inhibitor.
Schwartz JL; Kovalevsky G; Lai JJ; Ballagh SA; McCormick T; Douville K; Mauck CK; Callahan MM
Sex Transm Dis; 2008 Apr; 35(4):414-9. PubMed ID: 18362865
[TBL] [Abstract][Full Text] [Related]
18. A Phase I study of the functional performance, safety and acceptability of the BufferGel Duet.
Ballagh SA; Brache V; Mauck C; Callahan MM; Cochon L; Wheeless A; Moench TR
Contraception; 2008 Feb; 77(2):130-7. PubMed ID: 18226678
[TBL] [Abstract][Full Text] [Related]
19. Safety, tolerance and acceptability of the Invisible Condom and its vaginal applicator in healthy women and their male sexual partners.
Trottier S; Omar RF; Désormeaux A; Drouin J; Gagnon MT; Vezina F; Guilbert E; Mâsse B; Bergeron MG
Contraception; 2007 Aug; 76(2):117-25. PubMed ID: 17656181
[TBL] [Abstract][Full Text] [Related]
20. Safety, tolerability, and systemic absorption of dapivirine vaginal microbicide gel in healthy, HIV-negative women.
Nel AM; Coplan P; van de Wijgert JH; Kapiga SH; von Mollendorf C; Geubbels E; Vyankandondera J; Rees HV; Masenga G; Kiwelu I; Moyes J; Smythe SC
AIDS; 2009 Jul; 23(12):1531-8. PubMed ID: 19550287
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
